| Ticker Details |
Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company. It is engaged in the acquisition, development and commercialization of products to enhance cancer care. Its drug candidates are PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357.
|
| IPO Date: |
April 20, 2012 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$396.84M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.19 | 3.11%
|
| Avg Daily Range (30 D): |
$0.17 | 2.66%
|
| Avg Daily Range (90 D): |
$0.14 | 2.23%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.59M |
| Avg Daily Volume (30 D): |
.33M |
| Avg Daily Volume (90 D): |
.33M |
| Trade Size |
| Avg Trade Size (Sh.): |
116 |
| Avg Trade Size (Sh.) (30 D): |
63 |
| Avg Trade Size (Sh.) (90 D): |
69 |
| Institutional Trades |
| Total Institutional Trades: |
3,697 |
| Avg Institutional Trade: |
$2.06M |
| Avg Institutional Trade (30 D): |
$.52M |
| Avg Institutional Trade (90 D): |
$.67M |
| Avg Institutional Trade Volume: |
.05M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.63M |
| Avg Closing Trade (30 D): |
$.52M |
| Avg Closing Trade (90 D): |
$.76M |
| Avg Closing Volume: |
77.34K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$.62
|
$.27
|
$.62
|
|
Diluted EPS
|
$.61
|
$.26
|
$.61
|
|
Revenue
|
$228.37M
|
$75.45M
|
$228.37M
|
|
Gross Profit
|
$170.21M
|
$52.33M
|
$170.21M
|
|
Net Income / Loss
|
$31.11M
|
$13.44M
|
$31.11M
|
|
Operating Income / Loss
|
$37.3M
|
$17.11M
|
$37.3M
|
|
Cost of Revenue
|
$58.16M
|
$23.13M
|
$58.16M
|
|
Net Cash Flow
|
$-39.58M
|
$-23.89M
|
$-39.58M
|
|
PE Ratio
|
12.75
|
|
|
|
|
|
